Compare Sun Pharma with WYETH - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs WYETH - Comparison Results

SUN PHARMA     Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

WYETH 
   Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA WYETH SUN PHARMA/
WYETH
 
P/E (TTM) x 79.4 27.7 286.4% View Chart
P/BV x 3.4 5.3 63.3% View Chart
Dividend Yield % 0.6 1.3 49.3%  

Financials

 SUN PHARMA   WYETH
EQUITY SHARE DATA
    SUN PHARMA
Mar-20
WYETH
Mar-13
SUN PHARMA/
WYETH
5-Yr Chart
Click to enlarge
High Rs4841,044 46.4%   
Low Rs315818 38.5%   
Sales per share (Unadj.) Rs136.9298.6 45.8%  
Earnings per share (Unadj.) Rs17.557.2 30.5%  
Cash flow per share (Unadj.) Rs26.058.4 44.5%  
Dividends per share (Unadj.) Rs4.0017.00 23.5%  
Dividend yield (eoy) %1.01.8 54.8%  
Book value per share (Unadj.) Rs188.7249.5 75.6%  
Shares outstanding (eoy) m2,399.2622.72 10,560.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.93.1 93.6%   
Avg P/E ratio x22.916.3 140.8%  
P/CF ratio (eoy) x15.415.9 96.4%  
Price / Book Value ratio x2.13.7 56.8%  
Dividend payout %22.929.7 77.2%   
Avg Mkt Cap Rs m958,86421,157 4,532.2%   
No. of employees `00017.80.5 3,609.6%   
Total wages/salary Rs m63,624400 15,905.9%   
Avg. sales/employee Rs Th18,490.613,787.4 134.1%   
Avg. wages/employee Rs Th3,582.6813.0 440.7%   
Avg. net profit/employee Rs Th2,357.62,643.3 89.2%   
INCOME DATA
Net Sales Rs m328,3756,783 4,840.9%  
Other income Rs m6,360353 1,803.7%   
Total revenues Rs m334,7357,136 4,690.8%   
Gross profit Rs m69,8981,617 4,321.9%  
Depreciation Rs m20,52827 77,172.2%   
Interest Rs m3,0276 55,041.8%   
Profit before tax Rs m52,7021,938 2,719.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-2,606-5 51,105.9%   
Tax Rs m8,228632 1,301.5%   
Profit after tax Rs m41,8681,301 3,219.4%  
Gross profit margin %21.323.8 89.3%  
Effective tax rate %15.632.6 47.9%   
Net profit margin %12.819.2 66.5%  
BALANCE SHEET DATA
Current assets Rs m316,5426,984 4,532.4%   
Current liabilities Rs m157,0642,056 7,639.7%   
Net working cap to sales %48.672.6 66.9%  
Current ratio x2.03.4 59.3%  
Inventory Days Days8899 88.2%  
Debtors Days Days10524 437.4%  
Net fixed assets Rs m243,102244 99,509.7%   
Share capital Rs m2,399227 1,056.0%   
"Free" reserves Rs m450,2455,441 8,275.3%   
Net worth Rs m452,6455,668 7,986.0%   
Long term debt Rs m20,28925 81,156.8%   
Total assets Rs m682,5257,901 8,638.5%  
Interest coverage x18.4353.3 5.2%   
Debt to equity ratio x00 1,016.2%  
Sales to assets ratio x0.50.9 56.0%   
Return on assets %6.616.5 39.8%  
Return on equity %9.222.9 40.3%  
Return on capital %11.234.0 33.0%  
Exports to sales %00.2 0.0%   
Imports to sales %036.3 0.0%   
Exports (fob) Rs mNA15 0.0%   
Imports (cif) Rs mNA2,465 0.0%   
Fx inflow Rs m74,21915 488,280.9%   
Fx outflow Rs m27,9642,677 1,044.5%   
Net fx Rs m46,255-2,662 -1,737.6%   
CASH FLOW
From Operations Rs m65,548923 7,100.1%  
From Investments Rs m-25,888317 -8,169.3%  
From Financial Activity Rs m-57,151-481 11,881.8%  
Net Cashflow Rs m-13,857759 -1,825.4%  

Share Holding

Indian Promoters % 63.7 0.0 -  
Foreign collaborators % 0.0 51.1 -  
Indian inst/Mut Fund % 5.1 11.3 45.4%  
FIIs % 23.0 7.2 319.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 30.4 27.3%  
Shareholders   133,026 21,978 605.3%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   PROCTER & GAMBLE HEALTH  STERLING BIOTECH  ASTRAZENECA PHARMA  VENUS REMEDIES  IPCA LABS  

Compare SUN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 154 Points Lower, Nifty Ends at 14,834; Bajaj Finance and UPL Among Top Losers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended marginally lower.

Related Views on News

SUN PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 87.4% (Quarterly Result Update)

Feb 1, 2021 | Updated on Feb 1, 2021

For the quarter ended December 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 87.4% YoY). Sales on the other hand came in at Rs 88 bn (up 8.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2019-20 Annual Report Analysis (Annual Result Update)

Dec 11, 2020 | Updated on Dec 11, 2020

Here's an analysis of the annual report of SUN PHARMA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 66.9% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 66.9% YoY). Sales on the other hand came in at Rs 86 bn (up 5.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 31.6% (Quarterly Result Update)

May 28, 2020 | Updated on May 28, 2020

For the quarter ended March 2020, SUN PHARMA has posted a net profit of Rs 5 bn (down 31.6% YoY). Sales on the other hand came in at Rs 82 bn (up 14.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 29.8% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, SUN PHARMA has posted a net profit of Rs 10 bn (down 29.8% YoY). Sales on the other hand came in at Rs 82 bn (up 5.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

More Views on News

Most Popular

A Critical Update on the Market(Fast Profits Daily)

Mar 30, 2021

In this video, I'll tell you why I am recommending caution in the market at this time.

My Recent Recommendation Will Profit from the Global Supply Chain Crisis(Profit Hunter)

Mar 31, 2021

A tiny chemical company, started in the Licence Raj era, is a great example of a new wealth creating opportunity.

My Stock Trading Strategy(Fast Profits Daily)

Mar 31, 2021

In this video I'll show you exactly how I go about picking stocks for trading.

What You Need to Find Hundred Baggers(Profit Hunter)

Mar 30, 2021

100 baggers of the last decade share this common trait. Here's how to use it to nail future multibaggers.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Apr 9, 2021 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA - DISHMAN PHARMA COMPARISON

COMPARE SUN PHARMA WITH

MARKET STATS